GSK China Launches Initiatives Addressing Elderly Needs in Multiple Myeloma Diagnosis and Treatment

Economic Observer NetworkOn November 6, during the eighth China International Import Expo (CIIE), GSK launched an innovative initiative focused on patients with multiple myeloma (MM). It is reported that GSK will collaborate with the medical community and public welfare organizations. Through extensive social cooperation and continuous innovation in diagnosis and treatment, they aim to help patients overcome obstacles related to MM.

At the same time, to build a more comprehensive MM full-process support system, GSK and the Beijing Zhongkanglian Public Welfare Foundation officially signed a strategic cooperation memorandum. In the future, the two parties will establish an MM working group to improve MM management levels and reduce the management burden on doctors.

"Repeated relapses are one of the core challenges in the treatment of multiple myeloma, making effective intervention, especially during the initial relapse phase, critically important," pointed out Professor Fu Weijun from Shanghai Fourth People's Hospital, Tongji University. "The Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Plasma Cell Tumors has included the injectable Mabblenamab regimen as a Level I recommendation (Category 1 evidence) for the treatment of relapsed/refractory MM, becoming one of the standard regimens for the first relapse of MM."

Yuxiong Ke, Vice President and Head of Medical Affairs at GSK China, stated that Mabalant Monoclonal Antibody for Injection is an ADC drug. It efficiently delivers cytotoxic drugs by precisely targeting the BCMA antigen on the surface of MM cells, inducing apoptosis in tumor cells. Meanwhile, the monoclonal antibody in its structure enhances the body's immune response to improve anti-tumor effects.

Currently, the ADC therapy Belantamab Mafodotin Injection for relapsed/refractory MM, based on the results of the DREAMM-7 clinical study, has been included in the breakthrough therapy category by the Center for Drug Evaluation of the China National Medical Products Administration, and its marketing application has been accepted in China and is subject to the priority review and approval process. It is reported that GSK will continue to accelerate the R&D and introduction in the specialty medicine field.